

Cover Story
Conversation with The Cancer Letter
By Matthew Bin Han Ong
Will an oncologist of the not-so-distant future be able to pull up an image of a tumor biopsy slide on a screen and—without having to order a biomarker test—see the molecular characteristics of the cancer?
By Alexandria Carolan
In Brief


Clinical Roundup


Drugs & Targets


Trending Stories
- Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit - NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - An opportunity for Trump: Position U.S. cancer science to lead the world
- In the Headlines: “There’s no one to stand up for NCI right now.”
- Bhattacharya cancels NIH all-hands meeting
- The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”